1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response - None of the above
   
   
3. Who will be able to view these files?
   Response - Researchers who provide a methodologically sound proposal.
   


4. For what types of analyses will this data be available?
   Response - For individual participant data meta-analysis.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [srushtihireraddi@gmail.com].
   


6. For how long will this data be available start date provided 01-10-2027 and end date provided 01-10-2032?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Laparoscopic cholecystectomy is one of the most common surgical procedures performed for the removal of the gallbladder. The most common post operative problem reported after laparoscopic cholecystectomy is nausea and vomiting with prevalence of 27.7 percent.

Postoperative nausea and vomiting (PONV) causes dehydration, electrolyte imbalance and leads to discomfort and extended hospital stay. It also increases the risk of complications like aspiration pneumonia and wound dehiscence. Overall, it reduces the quality of life of patients and adds considerably to resource use and costs.

Several agents like 5HT3 antagonists, metoclopramide and domperidone are widely used as prophylaxis for postoperative nausea and vomiting but they are associated with sedation and extrapyramidal symptoms. Amisulpride is a selective dopamine (D2 and D3) antagonist that has been shown to be effective as a prophylactic antiemetic as well as a rescue treatment for postoperative nausea and vomiting. It has a better safety profile and more targeted action on D2 receptors in Chemoreceptor trigger zone of brain. It also has an additional benefit of minimal QT prolongation, which was a major concern with other D2 antagonists like droperidol.

Ondansetron is a 5HT3 receptor antagonist, which is considered to be very effective for postoperative nausea and vomiting management. Studies have shown promising results with amisulpride for postoperative nausea and vomiting in various clinical settings, but its application specifically in laparoscopic cholecystectomy remains unexplored. Studies comparing amisulpride with other antiemetics like ondansetron are lacking, hence this study comparing the efficacy of amisulpride to ondansetron is needed. The present study was designed to test the hypothesis that a single, preoperative 5mg IV dose of amisulpride was more effective than a single, preoperative 8mg IV dose of ondansetron at preventing PONV in adults undergoing laparoscopic cholecystectomy.